Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong: Evaluation of Immunogenicity and Safety of ICVAX in ART-treated Clinically Stable HIV-infected Patients

NCT07530198 is registered in ClinicalTrials.gov with Immuno Cure Holding (HK) Limited as lead sponsor.

NCT NCT07530198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07530198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong: Evaluation of Immunogenicity and Safety of ICVAX in ART-treated Clinically Stable HIV-infected Patients
Lead sponsor
Immuno Cure Holding (HK) Limited
Phase
Phase 1
Overall status
Recruiting
Start date
March 30, 2026
Completion date
July 31, 2027
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus, human immunodeficiency virus i infection